The study of markers of biological effect in cancer prevention research trials

✍ Scribed by Peter Greenwald; Karen M. Witkin; Winfred F. Malone; David P. Byar; Laurence S. Freedman; Harriet R. Stern

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: French
• Weight: 984 KB
• Volume: 52
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910520206

✦ Synopsis

Biological markers may provide a valuable tool for the development of cancer prevention agents, for monitoring patient compliance to a selected intervention, or for further defining the carcinogenic process. This discussion focuses on markers of biological effect and the rationale for their use in cancer prevention trials. Recent studies with biological markers are investigating their incorporation into phase-I, -11, and -111 chemoprevention clinical trial designs. Their use in clinical studies is expected to increase the number of agents that may be evaluated and to provide valuable information on the biological effectiveness of agents, doses, and schedules. Markers may also provide information to help in selecting high-risk groups for prevention research, and to indicate the pathways inhibited and the stage of carcinopenesis affected. Such information may prove of crucial importance in strengthening the rationale for long-term trials and other ancillary research. Biomarker research for colon carcinogenesis is discussed, including examples of a number of recent trials that may influence future progress in this area of prevention research. A crucial step in this process is marker validation as an aspect of major prospective observational and intervention studies where cancer incidence is the endpoint. We cannot be fully confident of markers as intermediate endpoints until the evidence from clinical trials is sufficiently strong ,to support major public health initiatives for prevention.